Press Releases

Pacira BioSciences to Present at Two Healthcare Conferences in November

TAMPA, Fla., Nov. 08, 2022 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:

  • Jefferies London Healthcare Conference on Tuesday, November 15th at 8:00AM GMT (3:00AM ET).
  • 34th Annual Piper Sandler Healthcare Conference on Tuesday, November 29th at 2:30PM ET.

Live audio of the events can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcasts will also be available for two weeks following the events.

About Pacira         

Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.


Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More